Exploring scientific publications by firms: Should firms have academic or corporate partners in order to publish?. McKelvey, M. & Rake, B. In
abstract   bibtex   
Recent research suggests that firms, particularly in science-based industries, publish scientific articles in order to achieve strategic goals. Since they often do so in collaboration with other organizations, this paper takes the next step by analyzing the influence of the number as well as the organization type of alliance partners on publication quality and impact. To make this argument, we analyze publications involving biotechnology or pharmaceutical firms and compare the results to publications that do not involve a firm. The empirical analysis is based on a unique dataset in pharmaceutical cancer research. The results indicate that firms need to carefully select their R&D alliance partners, as shown in the literature. Our results indicate that increasing the number of partners may have diminishing returns. More surprisingly, firms should focus on establishing R&D alliances with other firms to increase the probability of high-quality scientific publications. However, in terms of scientific impact, i.e., forward citations, firms do not benefit from having different types of alliance partners.
@inproceedings{mckelvey_exploring_2018,
	location = {Milano, Italy},
	title = {Exploring scientific publications by firms: Should firms have academic or corporate partners in order to publish?},
	abstract = {Recent research suggests that firms, particularly in science-based industries, publish scientific articles in order to achieve strategic goals. Since they often do so in collaboration with other organizations, this paper takes the next step by analyzing the influence of the number as well as the organization type of alliance partners on publication quality and impact. To make this argument, we analyze publications involving biotechnology or pharmaceutical firms and compare the results to publications that do not involve a firm. The empirical analysis is based on a unique dataset in pharmaceutical cancer research. The results indicate that firms need to carefully select their R\&D alliance partners, as shown in the literature. Our results indicate that increasing the number of partners may have diminishing returns. More surprisingly, firms should focus on establishing R\&D alliances with other firms to increase the probability of high-quality scientific publications. However, in terms of scientific impact, i.e., forward citations, firms do not benefit from having different types of alliance partners.},
	eventtitle = {Bocconi conference in memory of Luigi Orsenigo},
	author = {{McKelvey}, Maureen and Rake, Bastian},
	date = {2018},
}

Downloads: 0